Title 
A Multicenter Randomized Placebo -Controlled Trial of Intravenous Thyroxine for Heart -
Eligible Brain Dead Organ Donors  
 
NCT: 04415658  
 
APPENDIX A: Study Forms  
 
Document Date:  01 December 2 020  
A Multi -OPO Randomized Control Trial of T4 vs Placebo    Screening Worksheet  #1 
*To be filled out on EVERY   Brain -dead donor  
OPO: _____________________ ___ 
Donor UNOS  #: ______ __________  
Date: ____  / ____  / 20____  (mm/dd/ yyyy) 
Inclusion Criteria:   (Must have ALL 4 inclusion criteria)  
1. _____  Declared dead by neurologic criteria  
 
2. _____   Authorization for organ donation and research  
 
3. _____   Donor age 1 4-55 years  inclusive , and weight  ≥ 45 kg (100 lbs.)  
 
4. _____   Must be on 1 or more  of the following  vasopressors  and/or inotropes  at the start of 
the study : 
 
a. _____  norepinephrine  
b. _____  epinephrine  
c. _____  neosynephrine     
d. _____  dopamine  
e. _____  dobutamine  
f. _____  milrinone  
 
Exclusion Criteria:   (Must NOT  have any exclusion criteria)  
1. _____  Brain -death declared >24 hours ago  
2. _____  CAD or MI  (by hx, EKG, or previous cardiac cath)  that would exclude transplantation  
3. _____  Significant v alvular heart disease  (by hx or echo)  that would exclude transplantation  
4. _____  P revious sternotomy or cardiac surgery  
5. _____  Donor is in a VA hospital  
6. _____  Received IV or po  T4/T3  in the last month  (including home medication)  
7. _____  Known HIV+  serology  
8. _____  Other reason:_____________________________________________  
***If the donor has all 4 inclusion criteria and no exclusion criteria, he/she is eligible for the 
study and should be randomized to either T4 or NS, and the infusion should be started as 
soon as possible .***  
 
  ELIGIBLE  (go to worksheet)   NOT ELIGIBLE – STOP!  
All worksheets are to be submitted to the O PO research coordinator   
Revised 10/22/2020 
Worksheet #2  
Multi -OPO R andomized Control Trial of  T4 vs Placebo Data Collection Worksheet  
UNOS number: __________________        (revised 1 1/5/2020)  
OPO: _________________________________________________  
1. Admission to the hospital: Date: ____ / ____ / 20____; Time: ____:____ (all times in 24:00)  
2. Brain Death:                          Date: ____ /____ / 20____;  Time: ____:____  
Go to Sharepoint, Multi -OPO T4 RCT randomization sheet  to identify the next randomization.  
3. Randomized to:                   T4                                 NS 
***Draw free T4, TSH  prior to starting T4 / NS infusion.  
   
4a. Baseline results before starting T4 or saline:   Weight _______ kg  
      4b. Vent settings:  f _____  Vt  _____ cc  FiO2  _____  PEEP _____   PaO2 _____  
      Labs: (most recent before  starting protocol)  [enter 999 if data not available]  
c. Highest Troponin I (before starting protocol) _________ ng/ml  
d. ALT _________  
e. AST _________  
f. Bilirubin __________  
g. Creatini ne __________ BUN __________  
h. Amylase _________  
i. INR _________  
j. Calcium (total) _________ or  k. Calcium (ionized) _________  
 
 
5. T4 or NS started:  Date: ____ /____ / 20____;  Time: ____:____  
(needs to be  started  within 24 hours of brain -death declaration ) 
 
6. T4 rate:  30mcg/hr [ 500 mcg/ 500 cc NS at 30 cc/hr = 30 mcg/hr]  
a. Was T4 started at 30 mcg/hr   Yes ____    No ____  
b. If No, what was the reason: _______________________________________  
 
7.  NS rate 30 cc/hr  [should be equal to the normal T4 dose, i.e. 30 cc/hr] The donor may 
be on additional IV fluids as needed , but needs to have a separate IV of NS @ 30 cc/hr to 
match the fluid intake with the T4 protocol.  
a. Was NS started at 30 cc/hr?  Yes ____    No ____  
b. If No, what was the reason: ______________________________ _____________  
 
     ***   Please fill out the Multi -OPO RCT T4 Vasopressor Flow Sheet  #3.   ***  
 
***The only allowed doses of T4 are 30 mcg/hr, 20 mcg/hr, 10 mcg/hr .  Decrease the dose by   
10 mcg/hr,  if a lower dose is needed.***  
8. Was  the T4 dose decreas ed before 12 hours ?   Yes ____    No ____  
If Yes,  what was the reason? (check all that apply)  
a. ____Tachycardia (HR increased more than 20 bpm over baseline and is > 120 bpm)  
b. ____Hypertension (Systolic BP increased >30 mmHg and is >180 mmHg)  
c. ____Arrhythmia: ____ a fib/flutter; _____ SVT; _____ V tach; _____ PVCs (>6/min)  
d. ____Other: __________________________________________________  
 
9. Was the T4 dose stopped  before 12 hours ?    Yes ____   No ____  
If Yes,  what was the reason? (check all that apply)  
a. ____Tachycardi a (HR increased more than 20 bpm over baseline and is > 120 bpm)  
b. ____Hypertension (Systolic BP increased >30 mmHg and is >180 mmHg)  
c. ____Arrhythmia:  ____ a fib/flutter; _____ SVT; _____ V tach; _____ PVCs (>6/min)  
d. ____ Other: ________________________________ __________________  
 
10.  Time first echo ordered  after T4/NS started:                                                                         
Date: ____ /____ / 20____;  Time: ____:____  
 
11.  Ejection Fraction from first echo: __________%  
 
12.  If the donor was on T4 and completed the 12 -hour protocol, was the T4 stopped within 
60 minutes after the 12 -hour study period?  If the T4 stopped before 12 hours, answer 
N/A and go to #15.  
_____ Yes [skip to #15]     _____ No  [go to #13] _____N/A [skip to #15]  
If the donor was in the NS group, skip to question #1 4. 
 
13.  What was the reason  the T4 was continued beyond the study period ? 
a. Still on vasopressors   ________  
b. Still on inotropes   _________  
c. Physician’s preference ________  
d. Other  _____________________________________________  
e. Dose of  T4 __________ mcg/hr  
f. Time T4 stopped: Date: ____ /____ / 20____;  Time: ____:____  
Go to Question #15.  
  
 
 
14.  If the donor was randomized to NS, did the donor receive T4 after enrollment in the 
study (“open -label”)?   
____ Yes   ____ No            
 
If yes, what was the reason?  
a. Still on vasopressors   ________  
b. Still on inotropes   _________  
c. Physician’s preference _ _______  
d. Other  _____________________________________________  
e. Dose of open -label T4 __________ mcg/hr  
f. Time open -label T4 started: Date: ____ /____ / 20____;  Time: ____:____  
g. Time open -label T4 stopped: Date: ____ /____ / 20____;  Time: ____:____  
 
15.  If more than 1 echo was performed,  fill in the data below: [enter 999 in EF if not done]  
a. 2nd echo:  EF  _____ __%    Date: ____ /____ / 20____;  Time: ____:____  
b. 3rd echo:   EF  _____ __%    Date: ____ /____ / 20____;  Time: ____:____  
c. 4th echo:   EF  _____ __ %  Date: ____ /____ / 20____;  Time: ____:____  
 
   
Draw free T4  before going to the OR or at end of donor management  on all 
donors in the study ( T4 and control group ) 
 
16.  Baseline  Serum free T4 _________ ng/dl          TSH _________ mIU/L  
 
17.  Serum free T4 level  _________ ng/dl prior to OR . 
 
 
18. Was heart transplanted ? Yes______  No _________  
 
If heart not transplanted, what was the reason? (check all that apply)  
a. ____Decreased EF, poor function,  
b. ____ CAD :  1 vessel ____   2 vessel ____  3 vessel  ____  
c. ____LVH  
d. ____Size  
e. ____Medical history (smoking, diabetes, HTN, etc)  
f. ____Positive serologies  
g. ____Increased risk  
h. ____Match list exhausted  
i. ____Recipient issues  
j. ____Intra -op decline  
k. ____Surgical injury  
l. ____Valvular disease  
m. ____Other __________________________________  
 
  
 
 ADVERSE EVENTS : Please identify any new  adverse events that occurred in the donor, 
regardless if they received T4 or NS , after the start of the study:  
19.  Did the donor experience any of the following adverse events?   Yes ____ No ____  
If YES, ple ase check all that occurred:  
a.____ Severe hypertension (BP >200 mm Hg)  
b.____ Tachycardia (HR> 150; including sinus tach, SVT, PSVT)  
c.____ Fever (>102 degree)  
d.____ A fib or a flutter  
e.____ Ventricular ectopy (>6 VPCs/min,  bigeminy, trigeminy)  
f.____ V tach (spontaneously resolved)  
g.____ V tach (requiring cardioversion)  
h.____ V fib (requiring defibrillation)  
i.____ cardiac arrest * 
j.____ cardiac death prior to the OR * 
k.____ new skin rash  
l.____ other:  ___________________________________________________  
19 m. Was the adverse event related to the T4 infusion?    
 ____ YES  ____ NO  ____ UNCERTAIN  
19 n. Please describe the adverse event:  _______________________________________  
________________________________ _________________________________________  
*These events need to be reported  to the DSMB . 
              
20. Name of person filling out worksheet:  ________________________________________  
Date: ____________________________  
For the Research Coordinator:  After the case is completed, please upload the SRTR data to the 
Excel Spread sheet.
T4 Vasopressor Flow Sheet #3  
UNOS #: _____________________   OPO: _____________    Date Enrolled: _________               [randomized to    T4: ___   or  NS: ___ ]       
     BLOOD PRESSURE  VASOPRESSOR AND INOT ROPE DOSES (ENTER ZERO IF NOT ON  THE DRUG )  
INTERVAL  Time 
(Military)  
(HR:min)  T4 
Dose 
(mcg/
hr) Saline 
Dose  
(cc/hr)  Heart 
Rate   Invasive  
 Non-Invasive  Levophed*  
(mcg/min)  Epi*  
(mcg/kg/  
min)  Neo*  
(mcg/min)  Dopamine  
(mcg/kg/  
min)  Dobutrex*  
(mcg/kg/  
min)  Milrinone  
(mcg/kg/  
min)  Vaso*  
(U/hr)  
Sys Dias 
BASELI NE 
Before  first 
dose of  
T4/NS :             
2 HOUR S :             
4 HOUR S :             
6 HOUR S :             
8 HOUR S :             
10 HOUR S :             
12 HOUR S :             
END OF 
DONOR 
MGMT1              
12-hour intake: _____________ ml  Date  Vasopressor 
Ended  ___/___/___  ___/___/___  ___/___/___  ___/___/___  ___/___/___  ___/___/___    
 
12-hour output :_____________ ml  Time Vasopressor 
Ended  : : : : : : 
12-hour NET I/O: _____________  ml    *Norepinephrine  *Epinephrine  *Neosynephrine   *Dobutamine   *Vasopressin  
Date/Time T4 stopped  (Use Military Time):  _____ /_____ /_____   at   _____ :_____     
Notes/Comments:  _____________________________________________________________________________________________________  
Name of coordinator filling out worksheet: _______________________________________  
1 End of Donor Management is defined as when the donor was sent to the OR or was extubated in the ICU if no organs are procured . 
 